MyMD Earns Patent for Investigational Therapy MYMD-1

MyMD Earns Patent for Investigational Therapy MYMD-1

304015

MyMD Earns Patent for Investigational Therapy MYMD-1

MyMD Pharmaceuticals has secured a 13th U.S. patent protecting its experimental therapy MYMD-1, which is being investigated as a potential treatment for idiopathic pulmonary fibrosis (IPF) and other diseases. The new patent (11,096,933), “Method of Treating Disorders Associated with Chronic Inflammation,” covers the administration of MYMD-1 to treat disorders associated with chronic inflammation, with a particular focus on fibrosis (scarring) and asthma. “This latest patent underscores MYMD-1’s potential to inhibit inflammation, which is linked to…

You must be logged in to read/download the full post.